This report reveals how organizations in oligonucleotide, peptide and mRNA therapeutics are working and what key strategies changed in the last year.
In the last year, we have witnessed major advancements in the oligonucleotide, peptide, mRNA and gene edited therapeutics industry, particularly around mRNA vaccines and therapeutics in response to the pandemic.
However, what unique struggles have occurred in projects over the last year and what major changes have occurred in the industry as a whole?
In February 2021, we conducted a global survey of professionals working in oligonucleotide, peptide, mRNA and genome editing to find out how organizations in the industry are now working and what key strategies may have changed as a result of the COVID-19 pandemic.
This report is based on 118 responses and reveals the story so far, including the biggest challenges, advantages and transitions that different organizations in the industry have been facing across research, development, drug delivery and partnering.
In this analysis, we also compare the results with our previous State of the Industry Report published in 2019 to give a rounded view of what changes have arisen over this time.
